Minimal change disease is a glomerular disorder characterized by podocyte foot process effacement on electron microscopy with no visible changes on light microscopy, presenting as nephrotic syndrome most commonly in children.

Minimal Change Disease (MCD)

Parameter	Detail
Children	> 90% of childhood nephrotic syndrome ^[1]^[2]; peak age 2–6 years ^[3]
Adults	10–15% of adult nephrotic syndrome ^[1]^[2]^[3]
Sex	More common in males (M:F ≈ 2:1) in children ^[2]^[3]; roughly equal in adults
Ethnicity	More common in Asian and Caucasian populations ^[1]^[2]
Incidence (children)	~2–7 per 100,000 children per year globally
Elderly	When MCD presents in older adults, should alert to a possible underlying malignancy, especially of lymphoid origin (e.g. Hodgkin lymphoma) ^[2]
Hong Kong context	Given the large ethnic Chinese population, MCD is extremely common in paediatric nephrology practice. Secondary causes such as HBV-related glomerulonephritis must be excluded given the relatively higher HBV carrier rate in Hong Kong

Risk factors: male sex, young age (2–6 years), Asian/Caucasian ethnicity ^[1]^[2]^[3].

3. Anatomy & Function — The Glomerular Filtration Barrier

To understand MCD, you must understand the glomerular filtration barrier from first principles. The barrier has three layers, and MCD specifically targets the outermost layer:

4. Aetiology

Secondary causes of MCD ^[1]^[2]:

Category	Examples
Drugs	NSAIDs (most common drug cause), COX-2 inhibitors, antibiotics (ampicillin, rifampicin), lithium, penicillamine, bisphosphonates, 5-ASA derivatives (mesalazine), immunizations ^[1]^[2]^[3]
Neoplasms	Usually haematological malignancies — Hodgkin lymphoma (classic association), non-Hodgkin lymphoma, leukaemia ^[1]^[2]^[3]
Infections	Syphilis, TB, Mycoplasma, ehrlichiosis, HCV, Echinococcus, borreliosis ^[1]^[2]
Allergy	30% of MCD patients have a history of allergy (atopy, eczema, asthma) ^[1]^[2] — this fits with the T-cell/immune dysregulation hypothesis
Other glomerular diseases	IgAN, SLE, HIV nephropathy (may co-exist) ^[1]^[2]

High Yield — Drug-Induced MCD

NSAIDs are the most commonly implicated drugs in secondary MCD ^[2]^[3]. The mechanism is likely related to NSAID-mediated alteration of T-cell function and cytokine production, leading to podocyte injury. Always ask about NSAID use in any patient presenting with nephrotic syndrome.

High Yield — MCD and Hodgkin Lymphoma

The association between MCD and Hodgkin lymphoma is a classic exam favourite ^[1]^[2]^[3]. Hodgkin lymphoma is a disease of aberrant T cells (Reed-Sternberg cells), and MCD is thought to be mediated by T-cell dysfunction — so the pathogenetic link makes conceptual sense. In elderly patients presenting with MCD, always consider an underlying lymphoid malignancy.

5. Pathogenesis / Pathophysiology

5.3. Pathophysiology of Nephrotic Syndrome Features in MCD

Once massive proteinuria is established, the downstream consequences follow a logical cascade. The cardinal features of nephrotic syndrome are: heavy proteinuria > 3.5 g/day (> 40 mg/h/m² in children), generalised oedema, hypoalbuminaemia (< 30 g/L), hyperlipidaemia, and lipiduria ^[4]^[5].

Two theories explain oedema in nephrotic syndrome: the "underfill" theory and the "overfill" theory ^[5]:

Theory	Mechanism	When Applicable
Underfill	↓ serum albumin → ↓ plasma oncotic pressure → fluid shifts from intravascular to interstitial space → ↓ effective circulating volume → activation of RAAS and ADH → renal Na⁺/H₂O retention → worsens oedema	Classic in MCD (sudden, severe hypoalbuminaemia)
Overfill	Primary intrinsic renal Na⁺ retention (independent of albumin level) → plasma volume expansion → oedema	More relevant in nephritic-range diseases, but may contribute in MCD too

In MCD, the underfill mechanism predominates because the onset of proteinuria is abrupt and severe, causing a rapid drop in oncotic pressure before compensatory mechanisms can adapt.

6. Classification

Type	Description
Primary (Idiopathic)	No identifiable cause; vast majority of childhood cases
Secondary	Drug-induced (NSAIDs), malignancy-associated (Hodgkin lymphoma), infection-related, allergy-related

This classification is critical in clinical practice, especially in children ^[4]:

Category	Definition
Steroid-sensitive	Complete remission with standard steroid course
Steroid-dependent	2 consecutive relapses during tapering of steroids or within 14 days of cessation ^[4]
Steroid-resistant	Persistent proteinuria despite full-dose prednisolone × 4 weeks ^[4] (in children; 16 weeks often used in adults)
Frequently relapsing	≥ 2 relapses within 6 months of initial response, or ≥ 4 relapses within any 12-month period

Steroid-sensitive nephrotic syndrome (SSNS): MCD is the prototypical SSNS ^[1].

High Yield — Steroid-Resistant MCD

If a child with presumed MCD is steroid-resistant (10% of cases), you must repeat the renal biopsy ^[4]. The concern is that the original biopsy may have missed focal segmental glomerulosclerosis (FSGS) — sampling error can occur because sclerotic lesions in FSGS are "focal" (affecting < 50% of glomeruli) and "segmental" (affecting only part of a glomerulus). Some consider primary FSGS and MCD as part of a spectrum of disease caused by glomerular permeability factors — FSGS patients may have defective glomerular repair mechanisms, leading to progressive sclerosis ^[1]^[2].

Some authorities consider MCD and primary FSGS as two ends of the same disease spectrum ^[1]^[2]:

Feature	MCD	Primary FSGS
LM	Normal	Focal, segmental sclerosis
Steroid response	Excellent (> 90% children)	Partial (~50%)
Progression to ESRD	Very rare	Common (30–50% over 5–10 years)
Pathogenic concept	Permeability factor + intact repair	Permeability factor + defective glomerular repair mechanisms → progressive sclerosis ^[1]^[2]

7. Histopathology — The Three Pillars of Renal Biopsy

The key pathological features of MCD are ^[1]^[2]^[3]^[4]:

8. Clinical Features

Symptom	Pathophysiological Basis
Abrupt onset of generalised oedema (days to weeks) ^[1]^[2]^[3]	Massive proteinuria → hypoalbuminaemia → ↓ plasma oncotic pressure → third-spacing of fluid. MCD characteristically has a sudden onset unlike membranous nephropathy which is more insidious
Periorbital/facial oedema (especially in children, especially in the morning) ^[1]^[2]^[3]	Loose periorbital connective tissue allows fluid accumulation; worse in morning because gravity is evenly distributed during sleep (unlike dependent oedema of ankle)
Lower limb oedema / ankle swelling	Gravity-dependent oedema from low oncotic pressure; worse at end of day
Scrotal/vulval oedema ^[3]	Loose connective tissue in genital area; similar to periorbital oedema
Abdominal distension / ascites ^[3]	Fluid transudation into peritoneal cavity from low oncotic pressure
Abdominal pain ^[3]	Ascites, peritonitis (SBP — especially in nephrotic children), or bowel wall oedema causing ischaemia ^[3]
Dyspnoea ^[3]	Pleural effusion (transudative, from low oncotic pressure) and/or diaphragmatic splinting from tense ascites ^[3]
Frothy/foamy urine	Heavy proteinuria → protein in urine acts as a surfactant, reducing surface tension and creating foam
Oliguria (in some cases)	↓ Effective circulating volume (underfill) → ↓ renal perfusion → ↓ urine output
Weight gain	Fluid retention — patients may gain several kilograms over days
Constitutional symptoms: anorexia, fatigue, irritability ^[3]	Non-specific; related to hypoalbuminaemia, malaise from disease state
Preceding URTI or systemic infection ^[1]^[2]	MCD often follows an URTI or systemic infection ^[1]^[2]. Intercurrent infections may trigger T-cell activation → permeability factor release. This is also why relapses often follow infections
History of allergy/atopy	30% of MCD has history of allergy ^[1]^[2]. Reflects underlying immune dysregulation

Sign	Pathophysiological Basis
Generalised pitting oedema	Low oncotic pressure → interstitial fluid accumulation. Pitting because the oedema is transudate with low protein content, easily displaced
Periorbital puffiness	Loose periorbital tissue, especially prominent in children
Ascites (shifting dullness, fluid thrill)	Transudation into peritoneal cavity
Pleural effusion (↓ breath sounds, dullness at bases)	Transudation into pleural space
Blood pressure: usually normal or low	Unlike nephritic syndrome, MCD typically does NOT cause hypertension (no glomerular inflammation → no salt/water retention via overfill mechanism). However, if there is AKI or heavy RAAS activation, mild hypertension can occur
No gross haematuria	MCD causes bland, non-inflammatory glomerular damage. Microscopic haematuria occurs in only 20–25% ^[1]^[2]. Gross haematuria is NOT a feature of MCD and should make you think of other diagnoses (IgA nephropathy, PSGN, etc.)
Modestly ↑ serum creatinine in 30–40% ± AKI ^[1]^[2]	AKI can occur due to: (a) hypovolaemia from underfill, (b) interstitial oedema compressing tubules, (c) in rare cases, acute tubular necrosis
Leukonychia / Muehrcke's lines	Horizontal white bands on nails; reflect hypoalbuminaemia
Skin changes: xanthomata (rare)	Severe prolonged hyperlipidaemia
Signs of complications: leg swelling (DVT), pleuritic chest pain (PE), abdominal tenderness + fever (SBP)	Hypercoagulability, immunodeficiency (see pathophysiology above)

Key Clinical Features to Remember

The classic presentation of MCD is a child aged 2–6 years who develops sudden periorbital oedema 1–2 weeks after an URTI, with frothy urine and weight gain. Investigations show heavy proteinuria (highly selective), hypoalbuminaemia, hyperlipidaemia, and a bland urine sediment (no RBC casts). LM is normal; EM shows foot process effacement; IF is negative. The child responds dramatically to steroids.

Feature	MCD	FSGS	Membranous Nephropathy
Age	Children (2–6)	Adolescents/adults	Adults (> 40)
Onset	Abrupt	Insidious	Insidious
Proteinuria selectivity	Highly selective	Non-selective	Non-selective
Haematuria	≤ 25% microscopic	~50%	~30%
Hypertension	Uncommon	Common	Uncommon
Steroid response	Excellent (> 90%)	~50%	Poor without additional immunosuppression
Progression to ESRD	Very rare	30–50%	~33%
LM	Normal	Focal segmental sclerosis	Diffuse GBM thickening
IF	Negative	IgM, C3 (trapped in sclerotic areas)	Granular IgG, C3
EM	Foot process effacement	Effacement + sclerosis	Subepithelial deposits (spike & dome)

9. Relevant Investigations (Leading into Diagnosis — to be continued)

Feature	MCD (Nephrotic)	Typical Nephritic Disease (e.g. PSGN)
Urine sediment	Bland (no RBC casts)	Active (dysmorphic RBCs, RBC casts)
Proteinuria	Heavy, highly selective	Moderate, non-selective
Blood pressure	Usually normal	Hypertension
Complement	Normal	Low (C3 in PSGN)
LM	Normal	Proliferative changes
IF	Negative	Positive (IgG, C3)

High Yield Summary

Definition: MCD is a podocytopathy characterised by normal LM, diffuse podocyte foot process effacement on EM, and negative IF, presenting as nephrotic syndrome.

Epidemiology: > 90% of childhood nephrotic syndrome; 10–15% in adults. Peak age 2–6 years. Male > female. Asian/Caucasian predilection.

Aetiology: Mostly idiopathic. Secondary: NSAIDs (most common drug cause), Hodgkin lymphoma (classic malignancy association), infections, allergy (30%).

Pathogenesis: T-cell dysfunction → circulating permeability factor → podocyte foot process effacement → slit diaphragm disruption + charge barrier loss → massive selective proteinuria.

Histology triad: LM normal, EM foot process effacement, IF negative.

Clinical features: Abrupt onset nephrotic syndrome (often post-URTI) — periorbital oedema, frothy urine, weight gain, bland sediment. Microscopic haematuria in 20–25%. Modest ↑ creatinine in 30–40%.

Steroid response: Excellent — > 90% children, ~80–85% adults. Steroid resistance mandates repeat biopsy to exclude FSGS.

MCD-FSGS spectrum: Some consider these as two ends of the same podocytopathy spectrum; FSGS reflects defective repair → progressive sclerosis.

Key complications of nephrotic syndrome: Thromboembolism (AT III loss), infection/SBP (Ig loss), hyperlipidaemia, AKI.

Active Recall - Minimal Change Disease

Differential Diagnosis of Minimal Change Disease

1. Differential Diagnosis of Nephrotic Syndrome (The Master List)

Primary kidney diseases falling under the category of nephrotic syndrome include: focal segmental glomerulosclerosis, membranous glomerulopathy, minimal change disease, membranoproliferative glomerulonephritis (occasionally), and IgA nephropathy (occasionally) ^[6]^[7].

Non-proliferative GN is characterised by no increase in cellularity in the glomerulus and is associated with nephrotic syndrome. Proliferative GN is characterised by increase in cellularity in the glomerulus and is associated with nephritic syndrome ^[8].

The differential is best organised by age group (because the relative frequency of each cause changes dramatically with age) and by primary vs. secondary causes:

Age-stratified causes of nephrotic and nephritic syndrome ^[4]:

Age Group	Nephrotic (Non-Proliferative)	Nephritic (Proliferative)
< 15 years	MCD, FSGS	PSGN, IgAN/HSP
15–40 years	MCD, FSGS, Membranous	IgAN, PSGN, Lupus nephritis, RPGN
> 40 years	MCD, Membranous, DM, Amyloidosis	PSGN, IgAN, RPGN

In a child aged 2–6 with typical nephrotic syndrome, MCD is so overwhelmingly likely (> 90%) that empirical steroids are given without biopsy ^[1]^[2]^[4]. In an adult, MCD is only 10–15%, so you must consider the broader differential and usually need a renal biopsy.

Classification of glomerulonephritis by proliferative vs non-proliferative, and primary vs secondary ^[8]:

	Proliferative (Nephritic)	Non-Proliferative (Nephrotic)
Primary	IgA nephropathy; Membranoproliferative GN; Rapidly progressive (Crescentic) GN	Minimal change disease; Focal segmental glomerulosclerosis; Membranous nephropathy
Secondary	Post-streptococcal GN; Lupus nephritis; MPGN (HBV/HCV, autoimmune, malignancy); RPGN	Diabetic nephropathy; Hypertensive nephrosclerosis; Amyloidosis; Light chain deposition disease; FSGS (HIV, reflux, drug-induced); Membranous nephropathy (HBV/HCV, syphilis, malignancy, drug-induced)

2. Key Differential Diagnoses — Explained from First Principles

For each differential, I will explain why it can mimic MCD and how to distinguish it.

Primary FSGS may be misdiagnosed as MCD if biopsy does not hit the pathological glomeruli ^[1]^[2].

Why FSGS can mimic MCD:

Early FSGS affects only some glomeruli ("focal" = < 50% of glomeruli) and only parts of those glomeruli ("segmental"). If your biopsy needle samples a region of the kidney without sclerotic glomeruli, the LM looks completely normal — indistinguishable from MCD.
Both MCD and FSGS show foot process effacement on EM.
Both present with nephrotic syndrome.

Some consider primary FSGS and MCD as part of a spectrum of disease caused by glomerular permeability factors. FSGS patients may have defective glomerular repair mechanisms, leading to progressive sclerosis. On one end, MCD is very steroid responsive, associated with minimal glomerular changes, and usually does not progress into ESRD. On the other end, FSGS is not so steroid-responsive (only in ~1/2), associated with focal segmental sclerotic changes, and may result in progressive renal failure if severe proteinuria is persistent ^[1]^[2].

Feature	MCD	FSGS
LM	Normal	Focal segmental sclerosis (may be missed on biopsy)
EM	Diffuse foot process effacement	Foot process effacement + sclerotic segments
IF	Negative	IgM, C3 trapped in sclerotic areas
Proteinuria selectivity	Highly selective	Non-selective
Steroid response	> 90% children	~50%
Progression to ESRD	Very rare	30–50% over 5–10 years
Hypertension	Uncommon	More common
Microscopic haematuria	20–25%	More common (~50%)

High Yield — The Sampling Error Problem

Foot process effacement on EM is NOT a specific finding for MCD and is found in many proteinuria-associated glomerulopathies, e.g. FSGS ^[1]. If a patient is labelled as MCD but is steroid-resistant, you must repeat the renal biopsy ^[4] — the original biopsy may have missed sclerotic glomeruli of FSGS. Getting more glomeruli on re-biopsy increases the diagnostic yield.

MCD Variants that can also cause confusion:

MCD variants (e.g. IgM nephropathy, C1q nephropathy): usually more often associated with haematuria but may also show minimal LM findings on biopsy ^[1]. These have mesangial IgM or C1q deposits on IF respectively, but LM may look near-normal.

Membranous nephropathy is the most common cause of nephrotic syndrome in adults ^[4].

Why it enters the DDx:

Both cause nephrotic syndrome with heavy proteinuria.
Both are non-proliferative GN (no cellular proliferation on LM).

How to distinguish from MCD:

Feature	MCD	Membranous Nephropathy
Onset	Abrupt (days–weeks)	Insidious (weeks–months)
Age	Children 2–6	Adults > 40
LM	Normal	Diffuse GBM thickening ^[4]
EM	Foot process effacement only	Subepithelial electron-dense deposits ("spike and dome") ^[4]
IF	Negative	Granular staining — IgG/C3 ^[4]
Serology	Nothing specific	Anti-PLA2R antibody (primary MN) ^[4]
Secondary causes	NSAIDs, Hodgkin lymphoma	SLE, HBV/HCV, syphilis, malignancy (adenoCA — lung, prostate, GIT), drugs (captopril, gold, penicillamine) ^[4]
Steroid response alone	Excellent	Poor without additional immunosuppression
Prognosis	Excellent	Rule of thirds: 1/3 remit, 1/3 remain nephrotic, 1/3 progress to ESRD ^[4]

Hong Kong Context — HBV-Associated Membranous Nephropathy

In Hong Kong, the HBV carrier rate is ~7–8% of the population. Secondary causes of membranous nephropathy must be excluded, particularly hepatitis B which can cause membranous nephropathy treatable with antivirals ^[5]. Always check HBsAg, anti-HCV in any nephrotic patient in HK.

Before diagnosing nephrotic syndrome, non-renal causes of generalised oedema should be considered:

Condition	Key Distinguishing Feature
Congestive heart failure	Elevated JVP, S3 gallop, orthopnoea, BNP elevated; proteinuria mild
Liver failure/cirrhosis	Jaundice, spider naevi, ascites, ↓ albumin from liver synthetic failure; proteinuria absent or mild
Drug-related oedema (e.g. CCB)	Temporal relationship with drug initiation; no proteinuria ^[9]
Protein-losing enteropathy	Diarrhoea, ↓ albumin, no proteinuria

Features suggestive of MCD in a child (supporting empirical steroid trial without biopsy) ^[1]:

Feature	Rationale
Age between 1–10 years	Peak age for MCD
No macroscopic haematuria	Gross haematuria suggests IgAN, PSGN, or other proliferative GN
Normal blood pressure	Hypertension suggests nephritic component (MPGN, PSGN) or FSGS
Normal complement levels (C3, C4)	Low C3 suggests PSGN, lupus nephritis, or MPGN
Normal renal function	Significantly elevated creatinine at presentation suggests RPGN or other intrinsic renal disease

Exam Pearl — When NOT to Give Empirical Steroids in a Nephrotic Child

If any of the following are present, a renal biopsy should be performed instead of empirical steroid trial: age < 1 or > 10–12 years, gross haematuria, hypertension, low complement, impaired renal function, or features suggestive of secondary cause (rash, arthralgia, hepatitis).

Investigation	What It Helps Exclude	Expected in MCD
Serum complement (C3, C4)	Low in PSGN, lupus, MPGN	Normal
ANA, anti-dsDNA	SLE/lupus nephritis	Negative
Anti-PLA2R	Primary membranous nephropathy	Negative
HBsAg, anti-HCV	HBV/HCV-associated GN	Negative (but check in HK)
Serum protein electrophoresis	Myeloma, amyloidosis	No monoclonal band
Urine selectivity index	Selective → MCD; Non-selective → FSGS, membranous	Highly selective (< 0.2)
Electron microscopy on renal biopsy	The only imaging modality that can visualise the histopathological changes in MCD ^[6]	Diffuse foot process effacement
IF on renal biopsy	Positive in almost all other GN	Negative

Feature	MCD	FSGS	Membranous	MPGN	Diabetic Nephropathy	Amyloidosis
Peak age	2–6 y	Adolescent/adult	> 40 y	Any	Long-standing DM	> 60 y
Onset	Abrupt	Insidious	Insidious	Variable	Gradual	Gradual
Selectivity	Highly selective	Non-selective	Non-selective	Non-selective	Non-selective	Non-selective
Complement	Normal	Normal	Normal	Low (C3)	Normal	Normal
LM	Normal	Sclerosis	GBM thickening	Tram-tracking	Kimmelstiel-Wilson nodules	Congo red +
IF	Negative	IgM/C3 in sclerosis	IgG/C3 granular	C3 ± Ig	Non-specific	AA/AL typed
EM	FPE only	FPE + sclerosis	Subepithelial deposits	Subendothelial deposits	GBM thickening	Fibrils (8–12 nm)
Steroid response	> 90%	~50%	Poor alone	Variable	N/A	N/A
ESRD risk	Very low	High (30–50%)	Moderate (1/3)	High	High	High

High Yield Summary — DDx of MCD

FSGS is the single most important differential — may be misdiagnosed as MCD due to biopsy sampling error. Consider FSGS whenever a patient is steroid-resistant. Re-biopsy is mandatory.
Membranous nephropathy is the most common cause of adult nephrotic syndrome — distinguished by insidious onset, GBM thickening, subepithelial deposits, anti-PLA2R positivity.
NSAID-induced MCD + AIN is a classic exam scenario: nephrotic syndrome + AKI + eosinophilia + NSAID history. Dual pathology on biopsy.
In children aged 1–10 with typical features (no gross haematuria, normal BP, normal complement, normal RFT), the diagnosis is presumed MCD and empirical steroids are started without biopsy.
In adults, renal biopsy is required — the differential is too broad (membranous, FSGS, diabetic nephropathy, amyloidosis, myeloma) to treat empirically.
In the elderly with MCD, always screen for underlying lymphoid malignancy (especially Hodgkin lymphoma).
Normal complement in MCD distinguishes it from PSGN, lupus nephritis, and MPGN (all of which consume complement).

Active Recall - DDx of Minimal Change Disease

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p321 — MCD section, DDx, MCD variants) ^[2] Senior notes: Ryan Ho Urogenital.pdf (p77 — MCD section, DDx subsection) ^[4] Senior notes: Maksim Medicine Notes.pdf (p230–232 — Specific diseases table, age-stratified DDx) ^[5] Senior notes: learning_points_output.txt (Nephrology — Two Cases of Severe Proteinuria, Learning Point 3) ^[6] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (p21 — Primary nephrotic diseases, EM for MCD) ^[7] Lecture slides: Glomerular diseases.pdf (p54 — MCQ on DDx of glomerular disease) ^[8] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p995 — Classification table: proliferative vs non-proliferative, primary vs secondary) ^[9] Senior notes: Block A - Nephrology Interactive Tutorial.pdf (p3–4 — Case 2, NSAID-related MCD, red flags for non-diabetic nephropathy) ^[10] Senior notes: Block A – Nephrology Data Interpretation.pdf (p5 — LCDD, amyloidosis, myeloma DDx) ^[11] Senior notes: Ryan Ho Rheumatology.pdf (p70 — Lupus nephritis) ^[12] Senior notes: Block A - Drugs and the Kidney.pdf (p14 — NSAID-induced nephrotic syndrome + AKI)

Diagnostic Criteria, Diagnostic Algorithm, and Investigations for Minimal Change Disease

2. Diagnostic Criteria by Clinical Setting

In children, MCD is usually a clinical diagnosis → empirical glucocorticoids ^[1]^[2]^[4].

Suggestive features (supporting empirical steroid trial without biopsy) ^[1]:

Criterion	Rationale
Age between 1–10 years	Peak age for MCD; outside this range, other causes become more likely
No macroscopic haematuria	Gross haematuria suggests IgA nephropathy, PSGN, or other proliferative GN — not MCD
Normal blood pressure	Hypertension implies nephritic component (volume overload, glomerular inflammation) — unusual in MCD
Normal complement levels (C3/C4)	Low complement implies immune-complex-mediated GN (PSGN, lupus, MPGN) ^[13]^[14]
Normal renal function	Significant creatinine elevation suggests RPGN, severe FSGS, or tubulointerstitial disease

If all of these features are present → the child is treated as presumptive MCD with steroids. The diagnosis is confirmed retrospectively by the treatment response: complete remission within 4–8 weeks of steroids = steroid-sensitive nephrotic syndrome (SSNS), which is almost always MCD ^[4].

High Yield — When to Biopsy a Nephrotic Child

A renal biopsy IS indicated in children if atypical features are present:

Age < 1 year or > 10–12 years
Macroscopic haematuria
Hypertension
Low complement (C3/C4)
Renal impairment
Features of systemic disease (rash, arthralgia, hepatitis)
Steroid resistance: persistent proteinuria despite full-dose prednisolone × 4 weeks ^[4]

In adults, renal biopsy is generally required because the differential is broad ^[2]^[4].

The definitive diagnostic criteria for MCD on renal biopsy are the histological triad:

Modality	Finding	Why
Light microscopy (LM)	Normal glomerular morphology ("minimal change") ^[6]^[15]	No proliferation, no sclerosis, no GBM thickening, no crescents. The disease is a podocytopathy invisible to standard histology
Immunofluorescence (IF)	Negative for immunoglobulins ^[6]^[15]	MCD is NOT immune-complex-mediated. No antibody or complement deposits in the glomerulus
Electron microscopy (EM)	Total effacement of foot processes (podocytes) of visceral epithelial cells ^[6]^[15]	EM is the only imaging modality that can visualise the histopathological changes in MCD ^[6]. The foot processes flatten and fuse, obliterating slit diaphragms

"Light microscopy demonstrates essentially normal glomerular morphology, hence the term minimal change. Immunofluorescence is usually negative for immunoglobulins. The only detectable abnormality is the total effacement of foot processes (podocytes) of visceral epithelial cells shown on ultrastructural examination by electron microscopy." ^[15]

Critical Caveat from Lecture Slides

"These morphological alterations are typical of the nephrotic syndrome but not specific to MCNS. Podocyte effacement ≠ MCD → can also appear in other diseases, e.g. FSGS" ^[15]. This is a crucial exam point. Foot process effacement is a universal response of podocytes to injury — it occurs in FSGS, membranous nephropathy, diabetic nephropathy, and others. The combination of normal LM + negative IF + diffuse effacement on EM is what makes the diagnosis MCD, not the effacement alone.

4. Investigation Modalities — Systematic Approach

The investigations for a patient with suspected MCD serve three purposes:

Confirm nephrotic syndrome (proteinuria quantification, albumin, lipids)
Exclude secondary causes and other primary GN (serology, complement, imaging)
Establish definitive histological diagnosis (renal biopsy — the gold standard)

Test	Expected in MCD	Interpretation & Rationale
Urine dipstick	Protein 3–4+; RBC usually negative or trace	Screening test. Heavy proteinuria with bland sediment (no blood) is classic MCD. Presence of blood ≥ 2+ should trigger concern for proliferative GN
Urine microscopy	Bland/acellular sediment — oval fat bodies, fatty casts (Maltese cross under polarised light); NO dysmorphic RBCs, NO RBC casts	"Abrupt onset of oedema and nephrotic syndrome accompanied by acellular urinary sediment" ^[3]. RBC casts = glomerular haematuria → think IgAN, PSGN, lupus nephritis. Their absence is a key MCD feature
Urine protein quantification	Nephrotic range	"Gold standard is 24-hour quantification → but it is very cumbersome. Alternative: urine protein-to-creatinine ratio (uPCR) measured from first morning void" ^[16]. Nephrotic threshold: > 3.5 g/day (adults) or uPCR > 350 mg/mmol
UACR (urine albumin-to-creatinine ratio)	Markedly elevated	Used especially for diabetic patients / CKD patients. In QMH, uPCR is used instead of UACR ^[16]. UACR is more sensitive for early diabetic nephropathy but less commonly used for GN quantification
Urine selectivity index	Highly selective (< 0.2)	Calculated as clearance of IgG ÷ clearance of transferrin (or albumin). A low ratio means mostly albumin leaks (small, anionic protein) while IgG (larger) is retained → this indicates predominantly charge-barrier loss, which is characteristic of MCD. Non-selective proteinuria (index > 0.2) suggests FSGS or membranous nephropathy where both size and charge barriers are disrupted

Exam Pearl — Urine Selectivity Index

A highly selective proteinuria (selectivity index < 0.2) strongly favours MCD over other causes of nephrotic syndrome. However, this test is rarely used in modern clinical practice (it has been largely replaced by biopsy in adults). It remains conceptually important for exams and can support the clinical presumption in children.

Investigations to order when working up a case of potential nephrotic syndrome ^[6]:

Test	Expected in MCD	Why You Order It
Full blood count (CBC)	May show ↑ Hb (haemoconcentration from intravascular volume depletion); normal WCC; platelets may be ↑	Leucocytosis suggests infection or haematological malignancy. Eosinophilia → think NSAID-induced AIN ^[12]. Anaemia → think myeloma, SLE, CKD
Renal biochemistry (RFT)	Normal or modestly ↑ creatinine in 30–40% ^[1]^[2]	Document baseline renal function. When creatinine rises, GFR has already been reduced by at least 50% ^[9]. Significant elevation → concern for RPGN, ATN, or NSAID-induced AKI
Serum albumin	< 30 g/L (often < 20 g/L)	Confirms hypoalbuminaemia as part of nephrotic syndrome. Normal albumin = 34–54 g/L ^[9]
Lipid profile	↑ Total cholesterol, ↑ LDL, ↑ TG, ↓ HDL	Confirms hyperlipidaemia. Compensatory hepatic lipoprotein synthesis driven by low oncotic pressure
Fasting glucose / HbA1c	Normal (in primary MCD)	Fasting glucose is part of the standard nephrotic workup ^[6] to exclude diabetic nephropathy
Serum complement (C3, C4)	Normal	↓ C3/C4 generally indicates immune-complex-mediated GN: d/dx = MPGN, PSGN, lupus, cryoglobulinaemia, IE and shunt nephritis. Normal C3/C4 generally indicates non-IC-mediated GN ^[13]^[14]. This is a critical discriminator — MCD does NOT consume complement
Immune markers: ANA, anti-dsDNA	Negative	To exclude lupus nephritis
Anti-PLA2R antibody	Negative	Anti-PLA2R is specific for primary membranous nephropathy ^[4]^[6]. If positive, biopsy may not be needed for MN diagnosis
ANCA	Negative	To exclude ANCA-associated vasculitis / pauci-immune RPGN ^[13]^[14]
HBsAg, Anti-HCV, Anti-HIV	Negative (must check in HK)	HBV → secondary membranous nephropathy; HCV → MPGN or cryoglobulinaemic GN; HIV → collapsing FSGS ^[6]. HBV screening is particularly important in Hong Kong
Immunoglobulin (Ig) pattern / SPEP / serum free light chains	Polyclonal ↓ IgG (urinary loss); no monoclonal band	Ig pattern is part of the workup ^[6]. Monoclonal band → think myeloma, amyloidosis, light chain deposition disease
Tumour screening markers	Negative	In elderly MCD: "In elderly subjects, the onset of MCNS should arouse the suspicion of a possible underlying malignancy, particularly that of lymphoid origin, e.g. Hodgkin's disease" ^[15]. Order CXR, CT, stool OB as appropriate ^[6]

High Yield — Complement Levels as a DDx Tool

Serum complement level is important in helping narrow the differential diagnosis ^[13]^[14]:

Low C3/C4 → Immune-complex-mediated GN: PSGN, lupus nephritis, MPGN, cryoglobulinaemia, infective endocarditis
Normal C3/C4 → Non-IC-mediated GN: MCD, FSGS, membranous nephropathy, IgA nephropathy, ANCA vasculitis, anti-GBM disease

IgA-IgG immune complex in IgAN does NOT activate complement ^[13] — so IgAN has normal complement despite being immune-complex-mediated. This is a classic trick question.

Modality	Expected in MCD	Purpose
Renal ultrasound (USG)	Normal-sized kidneys (10–12 cm), symmetrical, no obstruction ^[17]	Best, most non-invasive way to assess and visualise kidneys ^[17]. Small kidneys → CKD (should NOT biopsy small kidneys — insufficient tissue and increased risk). Normal-sized kidneys with high creatinine → acute kidney injury / glomerulonephritis → will require a kidney biopsy ^[17]. Large kidneys → PKD, amyloidosis, obstruction
CXR	May show pleural effusions	Assess for pulmonary complications of nephrotic syndrome (pleural effusion) and as part of tumour screening in elderly
Doppler USG / CT angiography	Normal (unless complicated by renal vein thrombosis)	If RVT suspected: Doppler USG or CT angiography ^[4]. Indicated if sudden flank pain, worsening proteinuria, or unexplained AKI in a nephrotic patient

Renal biopsy is still essential for definitive diagnosis of a number of renal diseases, including glomerulonephritis — e.g. minimal change disease, FSGS, IgAN, membranous GN, membranoproliferative GN ^[18].

When is renal biopsy indicated in MCD?

Setting	Indication
All adults with nephrotic syndrome	Adults: immunological screen + renal biopsy (unless diagnosis obvious, e.g. DM nephropathy, PLA2R+) ^[4]
Children with atypical features	Age < 1 or > 10–12, gross haematuria, HTN, low complement, renal impairment
Children with steroid resistance	Steroid resistant (10%): persistent proteinuria despite full-dose prednisolone × 4 weeks → repeat renal biopsy ^[4]
Steroid-dependent/frequently relapsing	Not mandatory, but may be considered to confirm MCD and exclude early FSGS before starting second-line agents

What does the biopsy involve?

Diagnosis of renal diseases requires ^[18]^[19]:

Clinical history and manifestation (oliguria, haematuria, proteinuria, oedema, hypertension, loin pain)
Basic laboratory investigations (blood RFT; urine microscopy; urine protein quantification)
Renal biopsy — typically percutaneous under USG guidance. The tissue is processed for three types of examination:

Examination	Technique	What It Shows in MCD
Light microscopy	H&E staining, PAS staining, silver staining, Congo red staining ^[10]	Normal glomeruli ("minimal change"). PAS highlights basement membranes — normal in MCD. Silver stain shows GBM spikes in membranous nephropathy — absent in MCD. Congo red identifies amyloid — negative in MCD
Immunofluorescence	Detection of immunoglobulin deposits (IgG, IgA, IgM, C3, C1q) ^[10]	Negative — no deposits. This distinguishes MCD from IgA nephropathy (mesangial IgA), membranous (granular IgG/C3), and lupus nephritis ("full house" staining)
Electron microscopy	Ultrastructural examination of podocytes, GBM, and mesangium	Diffuse effacement (fusion) of podocyte foot processes — the sole abnormality. No electron-dense deposits (which would suggest immune complex disease)

Why Three Modalities Are Needed

No single modality can diagnose MCD alone:

LM alone: A "normal" biopsy on LM could also be early FSGS (sampling error), thin basement membrane disease, or early membranous before deposits are visible. You need IF and EM to discriminate.
EM alone: Foot process effacement is non-specific — it appears in ANY cause of heavy proteinuria ^[1]^[15]. You need LM + IF to exclude other causes.
IF alone: Negative IF can occur in FSGS and in pauci-immune RPGN. You need EM to confirm podocyte effacement. It is the combination of normal LM + negative IF + diffuse FPE on EM that makes the diagnosis.

Investigation	MCD Finding	Alternative Diagnosis If Different
uPCR	> 350 mg/mmol (nephrotic range)	Sub-nephrotic → consider IgAN, thin BM disease
Urine microscopy	Bland, acellular	Active sediment (dysmorphic RBCs, RBC casts) → nephritic GN
Selectivity index	< 0.2 (highly selective)	> 0.2 (non-selective) → FSGS, membranous
Serum albumin	< 30 g/L	> 30 g/L with nephrotic-range proteinuria → early disease or compensated
C3/C4	Normal	Low → PSGN, lupus, MPGN, cryoglobulinaemia
Anti-PLA2R	Negative	Positive → primary membranous nephropathy
ANA / anti-dsDNA	Negative	Positive → SLE / lupus nephritis
ANCA	Negative	Positive → ANCA vasculitis / pauci-immune RPGN
HBsAg	Negative	Positive → HBV-associated membranous or MPGN
SPEP / Free light chains	Normal / polyclonal	Monoclonal band → myeloma, AL amyloidosis, LCDD
Renal USG	Normal size (10–12 cm)	Small → CKD; Large → PKD, amyloid, obstruction
LM	Normal	Sclerosis → FSGS; GBM thickening → membranous; Proliferation → IgAN, PSGN
IF	Negative	IgA → IgAN; IgG/C3 granular → membranous; Full house → lupus; Linear IgG → anti-GBM
EM	Diffuse FPE, no deposits	Subepithelial deposits → membranous; Subendothelial → lupus/MPGN; Mesangial dense → IgAN

6. Special Diagnostic Scenarios

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p321 — Suggestive features, MCD diagnosis, FSGS DDx) ^[2] Senior notes: Ryan Ho Urogenital.pdf (p77 — MCD diagnosis, empirical glucocorticoids, DDx) ^[3] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p1001 — MCD clinical course: "acellular urinary sediment") ^[4] Senior notes: Maksim Medicine Notes.pdf (p230–232 — Children vs adults Ix approach, steroid resistance, specific diseases table) ^[6] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (p21–22 — EM for MCD, nephrotic syndrome workup investigations list) ^[9] Senior notes: Block A - Nephrology Interactive Tutorial.pdf (p3–4 — Normal creatinine, normal albumin values, red flags for non-diabetic nephropathy) ^[10] Senior notes: Block A – Nephrology Data Interpretation.pdf (p2, p5 — Biopsy processing: LM stains, IF, EM; myeloma/amyloidosis DDx) ^[12] Senior notes: Block A - Drugs and the Kidney.pdf (p7, p14 — NSAIDs and MCD, drug-induced glomerular diseases, NSAID-induced nephrotic syndrome + AKI) ^[13] Senior notes: Adrian Lui Pediatrics Notes.pdf (p325 — Complement levels in DDx, serology workup) ^[14] Senior notes: Ryan Ho Urogenital.pdf (p63 — Complement levels, serology workup for nephritic/nephrotic syndrome) ^[15] Lecture slides: Glomerular diseases.pdf (p39, p41 — MCNS definition, pathology description, podocyte effacement caveat) ^[16] Senior notes: Block A - Introduction to Renal Investigations (RFT, urine tests and US kidneys).pdf (p4 — uPCR vs 24hr protein, UACR) ^[17] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (p13 — Renal USG normal size, DDx of kidney size) ^[18] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (p3–4 — Renal biopsy essential for GN diagnosis, normal kidney histology) ^[19] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (p1 — AIN investigation, biopsy findings)

Management of Minimal Change Disease

3. General (Supportive) Management — Applicable to ALL Nephrotic Patients

This section is critical for SAQ exams ^[4]:

Furosemide ± Spironolactone ^[3]^[4]^[20]:

Agent	Mechanism	Notes
Frusemide (loop diuretic)	Blocks Na⁺-K⁺-2Cl⁻ co-transporter in thick ascending limb of Loop of Henle → ↓ sodium reabsorption → ↑ natriuresis + diuresis	First-line diuretic. ONLY indicated in severe symptomatic oedema with normal intravascular status ^[3]
Spironolactone (K⁺-sparing)	Aldosterone antagonist → blocks ENaC-mediated Na⁺ reabsorption in collecting duct	Can be added to decrease the risk of hypokalaemia ^[3] from frusemide
Thiazide diuretics	Blocks Na⁺-Cl⁻ co-transporter in DCT	Added for synergistic sequential nephron blockade when frusemide alone is insufficient

Danger — Diuretics in Nephrotic Syndrome

Diuretics may precipitate hypovolaemic shock, AKI, and increased thrombosis risk in a child with marked hypoalbuminaemia and intravascular volume depletion ^[3]. The "underfill" mechanism in MCD means the intravascular compartment is already depleted — aggressive diuresis can collapse the circulating volume. Always assess the intravascular status before diuresing.

Management of resistant oedema / anasarca ^[4]:

Problem	Cause	Solution
Resistant oedema	Poor drug/diet compliance; frusemide malabsorption due to gut wall oedema ^[4]	Change to IV frusemide; add thiazide / potassium-sparing diuretics; IV albumin ^[4]

Why does gut wall oedema cause frusemide malabsorption? Because frusemide is an oral medication absorbed in the GI tract. If the intestinal wall is oedematous (from low oncotic pressure), the drug cannot cross the mucosa efficiently → bioavailability drops → inadequate diuresis. Switching to IV bypasses this problem entirely.

IV albumin infusion can be used as adjunct to diuretics only for diuretic-resistant + oliguria/uraemia in absence of severe glomerular damage ^[20]. The rationale: albumin transiently raises plasma oncotic pressure, pulling fluid back intravascularly, where frusemide can then act on it. However, the infused albumin is rapidly lost in the urine in severe nephrotic syndrome, so the effect is temporary.

Anti-proteinuric therapy by angiotensin inhibitor (ACEI/ARB): indicated in ALL glomerulopathies ^[4]^[20].

Aspect	Detail
Mechanism	↓ intraglomerular pressure → ↓ proteinuria, which is associated with ↓ rate of GFR decline ^[20]. ACE inhibitors block angiotensin II, which normally constricts the efferent arteriole more than the afferent. By blocking this, the efferent arteriole dilates → intraglomerular pressure drops → less protein is forced across the GBM
Additional benefit	ACEI/ARB is also likely to ↓ hepatic lipoprotein production by reducing albumin loss in urine ^[20] — i.e. it helps with hyperlipidaemia indirectly
Goal	Keep proteinuria < 1 g/day or UPCR < 0.5–1 g/g ^[20]
Caution	Check for renal artery stenosis before starting (bilateral RAS → catastrophic ↓GFR with ACEI/ARB); monitor K⁺ and creatinine after initiation (initial ↑Cr up to 30% is acceptable)

Anti-thrombotic therapy by anticoagulants and ↓ immobilisation ^[20]:

Setting	Recommendation
No thromboembolic event	Usually only if thromboembolic events occur ^[20]. Prophylactic use usually NOT indicated unless otherwise indicated (e.g. AF), or high risk + ↓ bleeding risk (e.g. very low serum albumin < 20 g/L)
Thromboembolic event (DVT, PE, RVT)	Full anticoagulation. RVT without AKI: LMWH/UFH → warfarin for minimum 6–12 months while still nephrotic. RVT with AKI: thrombolysis ± embolectomy ^[4]
DVT prophylaxis	Compressive stockings ± anticoagulation if high risk ^[4]

4. Disease-Specific Therapy — Immunosuppression

1st line: high-dose prednisolone (1 mg/kg) × 4–8 weeks ^[4].

This is the cornerstone of MCD treatment. The rationale is straightforward: MCD is driven by T-cell dysfunction producing a circulating permeability factor. Glucocorticoids are potent immunosuppressants that:

Suppress T-cell activation and cytokine production → ↓ permeability factor
Have direct podocyte-stabilising effects → upregulate nephrin expression and stabilise the actin cytoskeleton
Result: podocytes recover → foot processes reform → slit diaphragm reconstituted → proteinuria resolves

Regimen details:

Parameter	Children	Adults
Induction dose	Prednisolone 60 mg/m²/day (max 80 mg/day) or 2 mg/kg/day	Prednisolone 1 mg/kg/day (max 80 mg/day)
Induction duration	4–6 weeks daily, then alternate-day tapering over 2–3 months	8–16 weeks (some use ≥ 16 weeks before declaring steroid resistance in adults)
Expected response	90% of children develop complete remission after 8 weeks of steroids ^[3]	80–85% of adults develop complete remission after 20–24 weeks of steroids ^[3]
Definition of remission	Urine protein nil or trace for 3 consecutive days	Urine protein < 0.3 g/day (or uPCR < 30 mg/mmol)

Overall prognosis is good. Good response to steroids ^[3]^[15].

High Yield — Steroid Side Effects to Monitor

High-dose steroids carry significant side effects, especially with prolonged or repeated courses:

Metabolic: Cushing's, hyperglycaemia, weight gain, dyslipidaemia
MSK: Osteoporosis, avascular necrosis of femoral head, myopathy
GI: Peptic ulcer, pancreatitis
Immune: Infection susceptibility (already increased in nephrotic syndrome)
Ophthalmic: Cataracts (posterior subcapsular), glaucoma
Growth: Stunted growth in children (major concern with repeated courses)
Psychiatric: Mood disturbance, psychosis

These side effects are the main reason to use steroid-sparing agents in frequently relapsing / steroid-dependent disease.

Steroid contraindications (relative):

Uncontrolled diabetes (steroids worsen glycaemia)
Active peptic ulcer disease (add PPI prophylaxis)
Active untreated infection (steroids immunosuppress)
Severe osteoporosis (add bisphosphonate + calcium/vitamin D)
Psychiatric vulnerability (monitor closely)

Clinical course definitions ^[4]:

Category	Definition	Frequency	Next Step
Steroid-sensitive (SSNS)	Complete remission with initial steroid course	~90% children, ~80% adults	Taper and observe
Steroid-dependent	2 consecutive relapses during tapering of steroids or within 14 days of cessation ^[4]	~30–50% of SSNS relapse at least once	Steroid-sparing agent
Steroid-resistant	Persistent proteinuria despite full-dose prednisolone × 4 weeks ^[4] (children); 16 weeks (some adult protocols)	~10% children	Repeat renal biopsy ^[4] → then CNI
Frequently relapsing (FRNS)	≥ 2 relapses within 6 months of initial response, or ≥ 4 relapses within any 12-month period	Subset of SSNS	Steroid-sparing agent
Infrequent relapse	Relapses that do not meet FRNS criteria	Variable	Re-treat with steroids

Indicated when: the patient is frequently relapsing, steroid-dependent, or experiencing unacceptable steroid side effects (e.g. growth retardation in children, Cushing's). The goal is to maintain remission while reducing cumulative steroid exposure.

2nd line: cyclophosphamide, cyclosporine ^[4]:

Agent	Class	Mechanism	Regimen	Key Points
Cyclophosphamide	Alkylating agent	Cross-links DNA → kills rapidly dividing cells including aberrant T cells. Provides a more durable remission by "resetting" the immune system	2–2.5 mg/kg/day for 8–12 weeks (single course, NOT repeated)	Preferred for FRNS/SDNS in children because one course can achieve lasting remission in ~50–70%. Cumulative dose limited to avoid toxicity. Contraindicated if steroid-resistant (poor response). S/E: leucopenia, infection, haemorrhagic cystitis (give mesna), gonadal toxicity (especially in boys — cumulative dose-dependent), alopecia, malignancy risk
Ciclosporin (cyclosporine)	Calcineurin inhibitor (CNI)	Inhibits calcineurin → blocks T-cell IL-2 production → suppresses T-cell activation. Also has direct podocyte-stabilising effects (stabilises actin cytoskeleton via synaptopodin)	3–5 mg/kg/day, therapeutic drug monitoring needed (trough 100–200 ng/mL)	Preferred for steroid-resistant MCD and for steroid-dependent patients who failed or cannot tolerate cyclophosphamide. High relapse rate when stopped (~60–80%). S/E: nephrotoxicity (chronic CNI nephrotoxicity with arteriolar hyalinosis — monitor Cr), hypertension, gingival hyperplasia, hirsutism, tremor, hyperuricaemia
Tacrolimus	Calcineurin inhibitor	Same as ciclosporin but more potent; binds FKBP-12 instead of cyclophilin	0.05–0.1 mg/kg/day, therapeutic drug monitoring	Alternative to ciclosporin with arguably fewer cosmetic S/E (no hirsutism/gingival hyperplasia) but more diabetogenic. Similar nephrotoxicity risk
Mycophenolate mofetil (MMF)	Anti-proliferative	Inhibits inosine monophosphate dehydrogenase → blocks de novo purine synthesis → selectively suppresses lymphocyte proliferation (lymphocytes are uniquely dependent on de novo pathway)	500–1000 mg BD in adults; weight-based in children	Used for FRNS/SDNS, particularly in adults. Fewer S/E than cyclophosphamide (no gonadal toxicity). S/E: GI (diarrhoea, nausea), leucopenia, infection. High relapse rate when stopped
Rituximab	Anti-CD20 monoclonal antibody	Depletes CD20⁺ B cells. Why does a B-cell depleting drug work in a T-cell-mediated disease? Likely because B cells serve as antigen-presenting cells for T cells, and rituximab may have off-target effects on T-cell regulation	375 mg/m² × 1–4 doses IV	Increasingly used for FRNS/SDNS refractory to cyclophosphamide and CNI. Can induce prolonged remission. S/E: infusion reactions, hypogammaglobulinaemia, progressive multifocal leukoencephalopathy (PML — rare), hepatitis B reactivation (screen HBsAg/anti-HBc before starting — very important in HK)

If MCD is secondary to an identifiable cause, the primary treatment is removing the offending trigger:

Cause	Action
NSAIDs	Stop the NSAID — the MCD (and AIN if coexistent) will often remit spontaneously after drug withdrawal. May add steroids if slow to resolve ^[12]
Hodgkin lymphoma / haematological malignancy	Treat the malignancy — MCD typically resolves with successful chemotherapy/radiotherapy for the lymphoma
Other drugs (lithium, bisphosphonates)	Withdraw the offending drug if possible
Infections	Treat the underlying infection
Allergy	Allergen avoidance where possible; treat with steroids as for primary MCD

Line	Agent	Dose	Duration	When to Use	Key S/E	Contraindications
1st	Prednisolone	1 mg/kg/day (adults); 60 mg/m²/day (children)	4–8 wk induction → taper	All MCD	Cushing's, DM, osteoporosis, growth suppression, infection	Uncontrolled DM, active infection (relative)
2nd	Cyclophosphamide	2–2.5 mg/kg/day	8–12 weeks (single course)	FRNS/SDNS in children	Leucopenia, gonadal toxicity, haemorrhagic cystitis, malignancy	Steroid-resistant MCD (poor response), pregnancy
2nd	Ciclosporin	3–5 mg/kg/day	Months–years; taper slowly	SDNS, FRNS, steroid-resistant MCD	Nephrotoxicity, HTN, gingival hyperplasia, hirsutism	Pre-existing renal impairment (relative), uncontrolled HTN
2nd	Tacrolimus	0.05–0.1 mg/kg/day	Months–years	Alternative to ciclosporin	Nephrotoxicity, DM, tremor, alopecia	Similar to ciclosporin
2nd	MMF	500–1000 mg BD	Months–years	SDNS/FRNS (especially adults)	GI upset, leucopenia	Pregnancy (teratogenic)
2nd/3rd	Rituximab	375 mg/m² IV × 1–4 doses	Single or repeated courses	Refractory FRNS/SDNS, failed cyclophosphamide/CNI	Infusion reactions, hypogammaglobulinaemia, PML, HBV reactivation	Active HBV, severe hypogammaglobulinaemia

Management of complications ^[4]:

Complication	Pathophysiology	Management
Resistant oedema / anasarca	Poor drug/diet compliance; frusemide malabsorption due to gut wall oedema	Change to IV frusemide; add thiazide / potassium-sparing diuretics; IV albumin ^[4]
AKI	Hypovolaemia due to over-diuresis; ATN; crescentic transformation (RPGN)	Lower dose / withhold diuretics; rehydration ^[4]. If RPGN → urgent renal biopsy and immunosuppression
Renal vein thrombosis	Hypercoagulability by compensatory production of clotting factors by liver	Doppler USG, CT angiography for diagnosis. If AKI: thrombolysis ± embolectomy. If non-AKI: LMWH/UFH → warfarin for minimum 6–12 months while still nephrotic ^[4]
SBP (only in children)	Loss of immunoglobulins	Antibiotics ^[4] — typically ceftriaxone or cefotaxime for S. pneumoniae / E. coli empirically
Cardiovascular disease	Long-term complications of hyperlipidaemia and hypercoagulability	CV risk modifications ^[4] — statins, lifestyle, BP control

Group	Outcome
Children with SSNS	Overall prognosis is good ^[3]^[15]. > 90% achieve remission. Most outgrow the disease by adolescence. ESRD is extremely rare
Frequently relapsing children	Chronic relapsing course but still generally good long-term renal prognosis. Main morbidity is from steroid side effects
Adults with MCD	80–85% develop complete remission after 20–24 weeks of steroids ^[3]. Slower response. Some have a relapsing course similar to children
Steroid-resistant (confirmed MCD)	Prognosis depends on response to second-line agents. A minority progress to CKD

High Yield Summary — Management of MCD

General supportive measures (SAQ-friendly — for ALL nephrotic syndrome):

Monitor: I/O, vitals, BW daily (aim 1 kg/day loss), urine dipstick ^[4]
Anti-oedema: low sodium diet + fluid restriction + frusemide ± spironolactone ^[4]
Anti-proteinuric: ACEI/ARB for ALL glomerulopathies ^[20] — ↓ intraglomerular pressure → ↓ proteinuria
Statins if persistent hyperlipidaemia ^[20]
DVT prophylaxis: compressive stockings ± anticoagulation if high risk ^[4]
Pneumococcal vaccination for ALL ^[20]

Disease-specific:

1st line: high-dose prednisolone (1 mg/kg) × 4–8 weeks ^[4]. 90% children / 80–85% adults remit.
2nd line: cyclophosphamide or cyclosporine ^[4] for FRNS/SDNS.
Steroid-resistant: repeat renal biopsy ^[4] → calcineurin inhibitor ± rituximab.
Secondary MCD: remove the cause (stop NSAID, treat lymphoma)

Complication management:

Resistant oedema → IV frusemide + IV albumin
AKI → withhold diuretics, rehydrate
RVT → anticoagulation (LMWH → warfarin 6–12 months)
SBP → antibiotics
Diuretics carry danger of hypovolaemic shock in underfilled patients

Active Recall - Management of MCD

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p321 — MCD suggestive features, empirical steroids) ^[2] Senior notes: Ryan Ho Urogenital.pdf (p77 — MCD diagnosis, empirical glucocorticoids) ^[3] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p1022 — General management, dietary modification, diuretics, steroid regimen, remission rates); MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p435 — identical content) ^[4] Senior notes: Maksim Medicine Notes.pdf (p230–232 — General management of NS, complication management table, steroid response definitions, specific diseases table) ^[5] Senior notes: learning_points_output.txt (Nephrology — Two Cases of Severe Proteinuria, Learning Points 1-3) ^[12] Senior notes: Block A - Drugs and the Kidney.pdf (p7, p14 — NSAID-induced MCD, drug-induced glomerular diseases) ^[15] Lecture slides: Glomerular diseases.pdf (p39, p41 — MCNS overview, prognosis, pathology) ^[20] Senior notes: Ryan Ho Fundamentals.pdf (p367–368 — General approach to NS management: ACEI/ARB, statins, anti-thrombotic, albumin infusion, pneumococcal vaccination, protein restriction not recommended)

Complications of Minimal Change Disease

1. Complications of the Nephrotic State

Prothrombotic state from increased hepatic clotting factor synthesis and urinary antithrombin III loss predisposing to deep vein and renal vein thrombosis ^[5].

Pathophysiology — explained from first principles:

The liver responds to the drop in plasma oncotic pressure (from hypoalbuminaemia) by ramping up protein synthesis non-specifically. This increased synthetic drive produces not only lipoproteins (causing hyperlipidaemia) but also clotting factors — particularly fibrinogen and factors V, VII, VIII, and X. Simultaneously, the damaged glomerular barrier allows urinary loss of anticoagulant proteins — most importantly antithrombin III (AT III, a small ~58 kDa protein that is readily filtered) and protein S. The net result is a gross imbalance: pro-coagulant factors are elevated while natural anticoagulants are depleted.

Additional pro-thrombotic factors:

Thrombocytosis — reactive; thrombopoietin production increases with hypoalbuminaemia
Platelet hyperaggregability — hyperlipidaemia and hypoalbuminaemia alter platelet membrane composition
Hyperviscosity — haemoconcentration from intravascular volume depletion (underfill)
Immobility — bed-bound oedematous patients with reduced physical activity

Thrombotic Event	Clinical Features	Notes
Deep vein thrombosis (DVT)	Unilateral leg swelling, pain, warmth, Homan's sign (unreliable)	Common. Diagnose with Doppler USG
Pulmonary embolism (PE)	Pleuritic chest pain, dyspnoea, tachycardia, hypoxia	Can be fatal. CT pulmonary angiography for diagnosis
Renal vein thrombosis (RVT)	Flank pain, haematuria, sudden worsening of proteinuria, AKI	Hypercoagulability by compensatory production of clotting factors by liver ^[4]. Classically associated with membranous nephropathy but can occur in any nephrotic state. Doppler USG, CT angiography for diagnosis ^[4]
Cerebral venous sinus thrombosis	Headache, seizures, focal neurological deficits	Rare but devastating. CT/MR venography

Management ^[4]:

Scenario	Treatment
RVT with AKI	Thrombolysis ± embolectomy ^[4]
RVT without AKI	LMWH/UFH → warfarin for minimum 6–12 months while still nephrotic ^[4]
DVT/PE	Standard anticoagulation (LMWH → warfarin/DOAC)
Prophylaxis	DVT prophylaxis: compressive stockings ± anticoagulation if high risk ^[4]

When Is Prophylactic Anticoagulation Justified?

Prophylactic anticoagulation is controversial but generally considered when serum albumin is very low ( < 20 g/L) and bleeding risk is acceptable. Membranous nephropathy carries the highest thromboembolic risk among nephrotic causes, but severe MCD with very low albumin also warrants vigilance. The risk-benefit calculation is individualised.

Infection risk from immunoglobulin loss and complement dysfunction ^[5].

Pathophysiology:

Why are nephrotic patients immunocompromised? Three reasons:

Urinary loss of immunoglobulins (especially IgG) — IgG (~150 kDa) is relatively large but still leaks through the severely damaged glomerular barrier. IgG is the principal opsonising antibody → its depletion impairs humoral immunity against encapsulated bacteria.
Urinary loss of complement factors — particularly factor B and factor D of the alternative complement pathway (these are small proteins readily lost in urine). Complement is critical for bacterial killing.
Oedematous tissue acts as a culture medium — fluid-laden subcutaneous tissue and peritoneal fluid provide an excellent environment for bacterial growth.
Immunosuppressive therapy (steroids, cyclophosphamide, CNI, rituximab) — further suppresses both humoral and cellular immunity.

Key infections in MCD:

Infection	Pathophysiology	Organisms	Management
Spontaneous bacterial peritonitis (SBP) — only in children ^[4]	Ascitic fluid with low protein (low opsonin content) → bacteria translocate from gut or seed haematogenously. Loss of Ig ^[4]	Streptococcus pneumoniae (most common), E. coli, Klebsiella	Antibiotics ^[4] — empirical ceftriaxone or cefotaxime; peritoneal fluid culture + sensitivity
Cellulitis	Oedematous skin with stretched, fragile integument → portal of entry for bacteria	Streptococcus, Staphylococcus	Antibiotics (flucloxacillin / co-amoxiclav)
Pneumonia	IgG and complement loss; steroid-induced immunosuppression	S. pneumoniae, Haemophilus, atypicals; PJP if heavily immunosuppressed	Empirical antibiotics; PJP prophylaxis (co-trimoxazole) if on prolonged immunosuppression
Septicaemia	Any of the above can become bacteraemic	Gram-positive and gram-negative organisms	Blood cultures; broad-spectrum IV antibiotics
Varicella zoster	Immunosuppression from steroids → primary VZV or reactivation can be severe / disseminated	VZV	Aciclovir; consider varicella-zoster immunoglobulin (VZIG) for exposed seronegative patients

High Yield — SBP in Nephrotic Children

SBP is essentially exclusive to nephrotic children ^[4] and is a surgical emergency mimicker (acute abdomen). The mechanism is peritoneal fluid + low opsonin activity + IgG loss. Always have a high index of suspicion in a nephrotic child with fever and abdominal pain — perform diagnostic paracentesis. S. pneumoniae is the classic organism, which is why pneumococcal vaccination is indicated for ALL nephrotic patients ^[20].

Modestly ↑ serum Cr in 30–40% ± AKI ^[1]^[2].

AKI in MCD can arise through multiple mechanisms:

Mechanism	Explanation	Management
Hypovolaemia due to over-diuresis ^[4]	Aggressive diuretic use in an underfilled patient collapses the intravascular volume → renal hypoperfusion → prerenal AKI	Lower dose / withhold diuretics; rehydration ^[4]
Severe underfilling	Profound hypoalbuminaemia → critically low effective circulating volume even without diuretics → prerenal AKI	IV albumin infusion to restore intravascular volume
ATN (acute tubular necrosis) ^[4]	Prolonged prerenal insult → tubular ischaemia → intrinsic renal AKI	Supportive: maintain euvolaemia, avoid nephrotoxins, monitor RFT
Interstitial oedema	Kidney interstitium becomes oedematous from low oncotic pressure → compresses tubules → ↓ GFR	Treat underlying nephrotic state (steroids → reduce proteinuria → restore oncotic pressure)
Crescentic transformation (RPGN) ^[4]	Rare but devastating: superimposed crescentic GN on top of MCD → rapidly progressive GFR decline	Urgent renal biopsy; pulse methylprednisolone ± cyclophosphamide/rituximab
Bilateral renal vein thrombosis	Thrombotic occlusion of renal venous outflow → congestion → AKI	Anticoagulation; thrombolysis if severe
NSAID-induced haemodynamic AKI	If patient is also taking NSAIDs: blocks prostaglandin-mediated afferent arteriolar dilation → ↓ GFR	Stop NSAIDs

Danger — Diuretic-Induced AKI

This is a common iatrogenic complication in nephrotic patients. The treating team sees massive oedema and gives high-dose IV frusemide. But the patient's intravascular compartment is already underfilled (the fluid is all in the interstitium). The diuresis further depletes the intravascular volume → renal hypoperfusion → AKI. Always assess volume status before diuresing — if JVP is flat and the patient is tachycardic, they are intravascularly dry despite their puffy appearance.

Resistant oedema / anasarca ^[4]:

Problem	Cause	Solution
Persistent oedema despite oral diuretics	Poor drug / diet compliance	Patient education; reinforce sodium restriction
	Frusemide malabsorption due to gut wall oedema	Change to IV frusemide ^[4]
Refractory to single agent	Diuretic resistance from renal tubular adaptation	Add thiazide / potassium-sparing diuretics ^[4] (sequential nephron blockade)
Severely symptomatic	Respiratory compromise from pleural effusions, tense ascites	IV albumin ^[4] as bridge + IV frusemide; consider paracentesis/thoracocentesis for tense effusions

Why does "sequential nephron blockade" work? Chronic loop diuretic use causes compensatory Na⁺ reabsorption in the distal convoluted tubule (DCT) via hypertrophy of DCT cells. Adding a thiazide blocks this compensatory mechanism. Similarly, aldosterone-driven Na⁺ reabsorption in the collecting duct can be blocked by spironolactone. By hitting three segments of the nephron simultaneously (loop + DCT + collecting duct), you maximise natriuresis.

2. Complications of Treatment

These are critically important because most MCD patients receive multiple steroid courses:

System	Complication	Mechanism
Metabolic	Cushing's syndrome (moon face, central obesity, striae, buffalo hump)	Exogenous cortisol excess mimicking Cushing's
Metabolic	Hyperglycaemia / steroid-induced DM	Steroids promote gluconeogenesis + insulin resistance
Metabolic	Weight gain	Appetite stimulation + fluid retention
MSK	Osteoporosis	↓ Osteoblast activity + ↑ osteoclast activity + ↓ intestinal Ca²⁺ absorption
MSK	Avascular necrosis of femoral head	Multifactorial: fat embolism, endothelial damage to intra-osseous vasculature
MSK	Proximal myopathy	Type II muscle fibre atrophy
Growth	Growth retardation in children	Suppression of GH/IGF-1 axis; impaired chondrocyte proliferation in growth plates
GI	Peptic ulcer disease	↓ Prostaglandin-mediated gastric mucosal protection; synergistic risk with NSAIDs
Immune	Infection susceptibility	Suppresses T-cell and neutrophil function → opportunistic infections (VZV, PJP, TB)
Ophthalmologic	Posterior subcapsular cataracts	Direct effect of steroids on lens epithelium
Ophthalmologic	Glaucoma	↑ Aqueous humour outflow resistance
Psychiatric	Mood disturbance, psychosis, insomnia	Effects on limbic system and neurotransmitter metabolism
Skin	Thin skin, easy bruising, acne	Collagen degradation, impaired wound healing
Adrenal	Adrenal suppression / crisis on withdrawal	Exogenous cortisol suppresses HPA axis; abrupt withdrawal → adrenal insufficiency

High Yield — Steroid Side Effects Are a Major Source of Exam Questions

In frequently relapsing MCD, the cumulative steroid burden is substantial. Growth retardation in children and osteoporosis in adults are the main drivers for switching to steroid-sparing agents. Always consider prophylaxis: vitamin D + calcium for bone protection; PPI if GI risk; PJP prophylaxis if prolonged high-dose immunosuppression.

Complication	Mechanism	Prevention
Leucopenia / pancytopenia	Alkylating agent → kills rapidly dividing cells including bone marrow precursors	Monitor CBC weekly; dose-adjust
Haemorrhagic cystitis	Acrolein (cyclophosphamide metabolite) is directly toxic to bladder urothelium	Mesna (sodium 2-mercaptoethane sulfonate) — binds acrolein in urine, neutralising it; adequate hydration
Gonadal toxicity	Damages germ cells → azoospermia (boys), premature ovarian failure (girls)	Cumulative dose-dependent; limit to one course; consider sperm/oocyte banking if old enough
Secondary malignancy	DNA cross-linking → mutagenesis → ↑ risk of bladder cancer, leukaemia	Minimise cumulative dose; long-term surveillance
Infection	Immunosuppression	Infection monitoring; prophylaxis as needed

Complication	Mechanism
Chronic nephrotoxicity	Arteriolar hyalinosis and interstitial fibrosis → progressive renal impairment. Paradoxical: you use a nephrotoxic drug to treat a kidney disease. Requires regular creatinine and drug level monitoring
Hypertension	Renal vasoconstriction → salt/water retention
Gingival hyperplasia (ciclosporin)	Fibroblast proliferation in gingival tissue
Hirsutism (ciclosporin)	Stimulation of hair follicle growth
Diabetes mellitus (tacrolimus > ciclosporin)	Direct β-cell toxicity → impaired insulin secretion
Tremor, neurotoxicity	CNI crosses blood-brain barrier → direct neurotoxic effects

Complication	Mechanism
Infusion reactions	Cytokine release from B-cell lysis
Hypogammaglobulinaemia	Prolonged B-cell depletion → ↓ immunoglobulin production → recurrent infections
Hepatitis B reactivation	Loss of B-cell-mediated immune surveillance allows latent HBV to reactivate. Critically important in Hong Kong — must screen HBsAg and anti-HBc before starting rituximab
Progressive multifocal leukoencephalopathy (PML)	JC virus reactivation in immunosuppressed state → fatal demyelinating brain disease. Very rare but devastating

While MCD itself has an excellent long-term renal prognosis, there are a few disease-specific issues:

Complication	Explanation
Frequent relapses	Up to 50–80% of children with MCD relapse at least once; 30–50% become frequently relapsing or steroid-dependent. Each relapse carries the risk of nephrotic complications + cumulative steroid toxicity
Steroid resistance / transformation to FSGS	A minority (~10%) are steroid-resistant. In some, this reflects true FSGS that was initially missed on biopsy (sampling error). In others, MCD may "transform" to FSGS over time — reflecting defective glomerular repair mechanisms leading to progressive sclerosis ^[1]^[2]. This is the only scenario where MCD-spectrum disease can progress to CKD/ESRD
Psychosocial impact	Chronic relapsing disease in a child → school absences, body image issues (Cushing's appearance from steroids), parental anxiety, medication fatigue. Often underestimated but significantly impacts quality of life

Category	Complication	Pathophysiology	Key Management
Nephrotic state	Thromboembolism (DVT, PE, RVT)	↑ Clotting factors + ↓ AT III (urinary loss) ^[4]^[5]	Anticoagulation; DVT prophylaxis: compressive stockings ± anticoagulation if high risk ^[4]
Nephrotic state	Infection / SBP	Loss of Ig ^[4]^[5]; complement dysfunction ^[5]	Antibiotics ^[4]; pneumococcal vaccination ^[20]
Nephrotic state	AKI	Hypovolaemia, ATN, crescentic transformation ^[4]	Withhold diuretics; rehydrate ^[4]; treat underlying cause
Nephrotic state	Resistant oedema	Gut wall oedema → frusemide malabsorption ^[4]	IV frusemide; add thiazide / K⁺-sparing; IV albumin ^[4]
Nephrotic state	Hyperlipidaemia / CV disease	↑ Hepatic lipoprotein synthesis + ↓ HDL ^[5]	Statins if persistent; CV risk modifications ^[4]
Nephrotic state	Hypothyroidism	Urinary TBG + T4 loss	TSH screening; levothyroxine if needed
Nephrotic state	Vitamin D deficiency / bone disease	Urinary DBP + 25-OH-D loss; compounded by steroids	Vitamin D + calcium supplementation
Nephrotic state	Iron-deficiency anaemia	Urinary transferrin loss	Iron supplementation
Treatment	Steroid toxicity (Cushing's, DM, osteoporosis, growth retardation, cataracts)	Exogenous cortisol excess	Minimise dose/duration; steroid-sparing agents for FRNS/SDNS; bone protection
Treatment	Cyclophosphamide toxicity (gonadal, haemorrhagic cystitis, malignancy)	Alkylating agent + acrolein metabolite	Limit cumulative dose; mesna; hydration
Treatment	CNI nephrotoxicity	Arteriolar hyalinosis	Drug level monitoring; dose adjustment
Treatment	Rituximab: HBV reactivation, PML	B-cell depletion → loss of immune surveillance	Screen HBV before starting; monitor
Disease-specific	Frequent relapses	Underlying T-cell dysregulation not cured by steroids	Steroid-sparing agents
Disease-specific	Transformation to FSGS	Defective repair → progressive sclerosis	Re-biopsy; CNI; rituximab

High Yield Summary — Complications of MCD

Complications of the nephrotic state (the "Big 5"):

Thromboembolism — ↑ clotting factors + ↓ AT III. DVT, PE, RVT. RVT + AKI → thrombolysis; RVT without AKI → warfarin ≥ 6–12 months.
Infection — IgG + complement loss. SBP in children (S. pneumoniae). Pneumococcal vaccine for ALL.
AKI — Over-diuresis (most common iatrogenic cause), ATN, crescentic transformation (rare). Withhold diuretics and rehydrate.
Resistant oedema — Gut oedema → frusemide malabsorption → switch to IV; sequential nephron blockade; IV albumin.
Hyperlipidaemia / CV disease — ↑ LDL/VLDL, ↓ HDL. Statins if persistent.

Complications of treatment:

Steroids: Cushing's, DM, osteoporosis, growth retardation (children), cataracts, infections
Cyclophosphamide: gonadal toxicity, haemorrhagic cystitis (use mesna), secondary malignancy
CNI: chronic nephrotoxicity (monitor drug levels), HTN, DM (tacrolimus)
Rituximab: HBV reactivation (screen in HK!), hypogammaglobulinaemia, PML

Prognosis: MCD has an overall good prognosis ^[3]. 90% children and 80–85% adults remit with steroids. ESRD is very rare. Main morbidity is from complications and treatment toxicity, not from progressive renal disease.

Active Recall - Complications of MCD

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p321 — MCD complications: AKI, haematuria; FSGS spectrum with defective repair) ^[2] Senior notes: Ryan Ho Urogenital.pdf (p77 — MCD clinical manifestations: ↑Cr, AKI; FSGS spectrum) ^[3] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p1001, p1015 — MCD prognosis, clinical manifestations); MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p408, p428 — identical content) ^[4] Senior notes: Maksim Medicine Notes.pdf (p230–232 — Management of complications table: resistant oedema, AKI, RVT, SBP, CV disease; DVT prophylaxis) ^[5] Senior notes: learning_points_output.txt (Nephrology — Two Cases of Severe Proteinuria, Learning Points 1–2: nephrotic syndrome complications) ^[20] Senior notes: Ryan Ho Fundamentals.pdf (p367–368 — General approach to NS management: pneumococcal vaccination, anti-thrombotic therapy, lipid-lowering)